Berkshire Money Management Inc. Makes New $107,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Berkshire Money Management Inc. bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $107,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Orion Capital Management LLC raised its holdings in Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter worth about $74,000. Atria Investments Inc bought a new position in shares of Anavex Life Sciences in the 3rd quarter worth about $76,000. BNP Paribas Financial Markets lifted its position in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 7,421 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 6,366 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

NASDAQ:AVXL opened at $8.87 on Wednesday. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The firm has a 50-day simple moving average of $9.98 and a two-hundred day simple moving average of $7.61.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, research analysts forecast that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AVXL has been the subject of a number of analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Tuesday, January 28th. HC Wainwright reaffirmed a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday, January 28th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.